These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31678711)

  • 1. Effect of rivaroxaban and dabigatran on platelet functions: in vitro study.
    Jourdi G; Bachelot-Loza C; Mazoyer E; Poirault-Chassac S; Duchemin J; Fontenay M; Gaussem P
    Thromb Res; 2019 Nov; 183():159-162. PubMed ID: 31678711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
    Nakazaki M; Oka S; Magota H; Kiyose R; Onodera R; Ukai R; Kataoka-Sasaki Y; Sasaki M; Honmou O
    J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106520. PubMed ID: 35523052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
    Olivier CB; Weik P; Meyer M; Weber S; Diehl P; Bode C; Moser M; Zhou Q
    J Thromb Thrombolysis; 2016 Aug; 42(2):161-6. PubMed ID: 26961375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
    Olivier CB; Weik P; Meyer M; Weber S; Anto-Michel N; Diehl P; Zhou Q; Geisen U; Bode C; Moser M
    Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
    Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
    PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
    Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations.
    Godier A; Martin AC; Leblanc I; Mazoyer E; Horellou MH; Ibrahim F; Flaujac C; Golmard JL; Rosencher N; Gouin-Thibault I
    Thromb Res; 2015 Oct; 136(4):763-8. PubMed ID: 26319422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban.
    Wan H; Yang Y; Zhu J; Wu S; Zhou Z; Huang B; Wang J; Shao X; Zhang H
    Blood Coagul Fibrinolysis; 2016 Dec; 27(8):882-885. PubMed ID: 26757012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
    Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
    Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000.
    Artang R; Brod C; Nielsen JD
    Semin Thromb Hemost; 2022 Oct; 48(7):808-813. PubMed ID: 36174600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
    Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
    J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.